ClinVar Miner

Submissions for variant NM_000133.4(F9):c.1173T>A (p.Tyr391Ter)

dbSNP: rs1603267411
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV001000168 SCV001156657 pathogenic not specified 2019-02-14 criteria provided, single submitter clinical testing The F9 c.1173T>A; p.Tyr391Ter variant, also reported as Tyr345Ter, has been described in at least one individual affected with hemophilia B (see like to F9 database and references therein, Wulff 1995). It is absent from the general population databases (Exome Variant Server and Genome Aggregation Database), indicating it is not a common polymorphism. This variant induces an early termination codon; although the mRNA may not be targeted for nonsense-mediated decay, if a stable protein product is produced then it would be truncated and lack the final 71 amino acid residues which are likely crucial for normal protein function. Several downstream truncating variants have been described in individuals affected with hemophilia B and are considered pathogenic (see link to F9 database and references therein). Based on available information, p.Tyr391Ter is considered pathogenic. REFERENCES Link to F9 database: http://www.factorix.org/ Wulff K et al. Twenty-five novel mutations of the factor IX gene in haemophilia B. Hum Mutat. 1995;6(4):346-8.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.